Bcr-Abl
Bcr-Abl inhibitors are targeted therapies that inhibit the Bcr-Abl fusion protein, which is formed due to the Philadelphia chromosome translocation and is a driver of chronic myeloid leukemia (CML). This protein also influences angiogenesis, contributing to tumor progression. Bcr-Abl inhibitors are crucial in the treatment of CML and are being explored for their potential in inhibiting angiogenesis in various cancers. At CymitQuimica, we provide high-quality Bcr-Abl inhibitors to support your research in cancer biology, angiogenesis, and targeted therapy.
Found 129 products for "Bcr-Abl".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
GNF-5
CAS:GNF-5, non-ATP Bcr-Abl inhibitor (IC50: 0.22±0.1 uM, wild-type), improves upon GNF-2 with better pharmacokinetics.Formula:C20H17F3N4O3Purity:98% - 99.94%Color and Shape:SolidMolecular weight:418.3692Flumatinib mesylate
CAS:Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.Formula:C30H33F3N8O4SPurity:99.82%Color and Shape:SolidMolecular weight:658.694CZC-8004
CAS:CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.Formula:C17H16FN5Purity:99.29%Color and Shape:SolidMolecular weight:309.3408Adaphostin
CAS:Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.Formula:C24H27NO4Purity:98.29%Color and Shape:White SolidMolecular weight:393.48Nilotinib monohydrochloride monohydrate
CAS:Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosineFormula:C28H22F3N7O·HCl·H2OPurity:99.93%Color and Shape:SolidMolecular weight:583.99AST 487
CAS:AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.Formula:C26H30F3N7O2Purity:98.17% - 99.56%Color and Shape:SolidMolecular weight:529.56PD173955
CAS:PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR andFormula:C21H16Cl2N4OSPurity:98.99% - 99.83%Color and Shape:SolidMolecular weight:443.349Bosutinib hydrate
CAS:Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.Formula:C26H31Cl2N5O4Purity:99.99%Color and Shape:White SolidMolecular weight:548.461cSRC/BCR-ABL-IN-1
cSRC/BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.Formula:C29H31Cl2N5O4Color and Shape:SolidMolecular weight:584.494CpCDPK1/TgCDPK1-IN-1
CAS:CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.Formula:C18H17N5Purity:99.98%Color and Shape:SolidMolecular weight:303.36CHMFL-ABL-053
CAS:CHMFL-ABL-053: potent, selective BCR-ABL/SRC/p38 inhibitor (IC50: 70/90/62 nM). Orally available, potential CML drug.Formula:C28H26F3N7O2Color and Shape:SolidMolecular weight:549.55BCR-ABL-IN-5
CAS:BCR-ABL-IN-5: Bcr-Abl kinase inhibitor, IC50: Bcr-AblWT 0.014 μM, Bcr-AblT315I 0.45 μM; anti-leukemia cell growth.Formula:C25H21Cl2N5O2Color and Shape:SolidMolecular weight:494.37AFG210
CAS:AFG210 is a novel first-generation “type II” FLT3 inhibitor.Formula:C19H14F3N3O2Color and Shape:SolidMolecular weight:373.33BCR-ABL1-IN-1
CAS:BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.Formula:C18H12F3N3O2Color and Shape:SolidMolecular weight:359.3AP 24149
CAS:AP 24149, a potent dual inhibitor targeting Src and Abl, exhibits IC50 values of 9.1 nM for Src and 3.6 nM for Abl, respectively.Formula:C23H24N5OPColor and Shape:SolidMolecular weight:417.44BCR-ABL-IN-7
CAS:BCR-ABL-IN-7 is an inhibitor of ABL kinase activity in WT and T315I mutants.BCR-ABL-IN-7 can be used in chronic myeloid leukemia (CML) research.Formula:C19H16FN3O3SPurity:99.57%Color and Shape:SolidMolecular weight:385.41BCR-ABL-IN-6
CAS:BCR-ABL-IN-6, an imatinib derivative, inhibits Bcr-AblWT (4.6 nM IC50) and T315I (277 nM), for chronic myeloid leukemia study.Formula:C27H22F3N5O2Color and Shape:SolidMolecular weight:505.49PF-06651481-00
CAS:PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.Formula:C26H29Cl2N5O3Purity:97.01%Color and Shape:SolidMolecular weight:530.446BCR-ABL-IN-1
CAS:BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.Formula:C23H21F4N5OPurity:98%Color and Shape:SolidMolecular weight:459.44c-ABL-IN-2
CAS:C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.Formula:C21H20N4OColor and Shape:SolidMolecular weight:344.41
